Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

New treatment approach may benefit relapsed post-transplant blood cancer patients

For many patients with advanced blood cancers, a stem-cell transplant can drive the disease into remission. However, about one-third of these patients experience a relapse and face a very poor prognosis.

13 Jul 2016

Study shows how increase in BMI contributes to multiple myeloma growth and progression

In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients.

12 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

TUM researchers uncover molecular mechanism of thalidomide

In the 1950s, thalidomide (Contergan) was prescribed as a sedative drug to pregnant women, resulting in a great number of infants with serious malformations. Up to now, the reasons for these disastrous birth defects have remained unclear.

20 Jun 2016

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive’s high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry.

16 Jun 2016

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.

15 Jun 2016

NCCN educational resources provide insight for patients with Mycosis Fungoides

Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States.

13 Jun 2016

Carfilzomib therapy shows promise for pre-kidney transplant patients

Early findings by researchers at the University of Cincinnati College of Medicine suggest that the use of a second generation cancer drug, carfilzomib, may provide an improved approach for the reduction of antibodies in potential kidney transplant candidates.

10 Jun 2016

Researchers discover AF1q protein linked to multiple myeloma, EMD

A group of researchers from the University of Louisville, Japan and Austria is the first to identify a protein, AF1q, associated with multiple myeloma and a condition that occurs in approximately one-fourth of very aggressive multiple myeloma, extramedullary disease or EMD.

10 Jun 2016

Scientists discover unexpected functions of snoRNAs that explains cause of some diseases

Scientists have discovered unexpected functions of small nucleolar RNAs (snoRNAs) that explain the cause of some diseases.

7 Jun 2016

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive results regarding overall survival.

6 Jun 2016

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer.

1 Jun 2016

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

21 May 2016

New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).

18 May 2016

Novel animal model helps understand mechanisms that lead to multiple myeloma

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an animal model that allows them to better understand the mechanisms that lead to the development of multiple myeloma, a hematologic cancer of plasma cells, and the amyloidosis that sometimes accompanies it. The study was published in the journal Scientific Reports.

6 May 2016

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges.

30 Apr 2016

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center.

29 Apr 2016

Series of routine tests may not be beneficial to patients with age-related disorder

A series of tests physicians routinely order to help diagnose and follow their patients with an elevated antibody level that is a marker for cancer risk, often do not benefit the patient but do increase health care costs, pathologists report.

27 Apr 2016

Rab inhibition may be a promising antimyeloma strategy

Roswell Park Cancer Institute researchers are investigating agents that target and disrupt the trafficking of monoclonal antibodies in multiple myeloma, a cancer of the bone marrow. The results will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.

22 Apr 2016

PPP3CA, calcineurin may be suitable therapeutic targets for multiple myeloma treatment

Multiple myeloma (MM) is a hematological cancer that frequently acquires resistance to chemotherapeutic drugs. Additionally, many patients experience disease relapse, but these patients are difficult to treat as the cancer is often resistant to the previous treatment regimen.

22 Apr 2016

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

New treatment approach may benefit relapsed post-transplant blood cancer patients

Study shows how increase in BMI contributes to multiple myeloma growth and progression

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

TUM researchers uncover molecular mechanism of thalidomide

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

NCCN educational resources provide insight for patients with Mycosis Fungoides

Carfilzomib therapy shows promise for pre-kidney transplant patients

Researchers discover AF1q protein linked to multiple myeloma, EMD

Scientists discover unexpected functions of snoRNAs that explains cause of some diseases

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

Novel animal model helps understand mechanisms that lead to multiple myeloma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

Series of routine tests may not be beneficial to patients with age-related disorder

Rab inhibition may be a promising antimyeloma strategy

PPP3CA, calcineurin may be suitable therapeutic targets for multiple myeloma treatment

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in